Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation
NCT ID: NCT01014247
Last Updated: 2013-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
56 participants
INTERVENTIONAL
2009-11-30
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
NCT06649942
A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers
NCT01107054
Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects
NCT01140425
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
NCT02257398
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
NCT01359618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Avelox (Moxifloxacin, BAY12-8039)
Single dose of 400 mg
Arm 2
Placebo
Single dose of matching tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avelox (Moxifloxacin, BAY12-8039)
Single dose of 400 mg
Placebo
Single dose of matching tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer HealthCare Pharmaceuticals Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Melbourne, Victoria, Australia
Giessen, Hesse, Germany
Dresden, Saxony, Germany
Singapore, , Singapore
Singapore, , Singapore
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-012363-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
13796
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.